Skip to main content
COCH
NASDAQ Industrial Applications And Services

Envoy Medical Q2 2026: Cash Runway Through Q1 2027, Going Concern Doubt Persists

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.693
Mkt Cap
$51.603M
52W Low
$0.363
52W High
$1.89
52W Position info
91% above low
Off High info
63% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

COCH sits 91% above its 52-week low of $0.363 on light trading volume (0.2× avg).

Summary

Envoy Medical's Q2 2026 10-Q shows a cash runway only through Q1 2027, persistent going concern doubts, and unremediated material weaknesses — offset by clinical progress in its Acclaim cochlear implant trial.


Key Events · Earnings and Guidance · COCH

  • Going Concern Doubt Reiterated

    Cash of $19.7 million as of June 30, 2026 will not fund operations beyond Q1 2027. Management's plans to raise capital through warrant exercises or other financing are not assured.

  • Material Weaknesses Unremediated

    Disclosure controls remain ineffective due to material weaknesses in risk assessment, accounting policies, and IT general controls — remediation is ongoing but not yet complete.

  • Clinical Trial Progress

    All 56 patients in the Acclaim pivotal trial have passed the 3-month milestone. The first module of the PMA application was submitted June 30, 2026, with final module expected in early Q2 2027.

  • Cash Burn Accelerating

    Operating cash outflow was $11.5 million in H1 2026, up from $8.2 million in H1 2025, driven by increased clinical trial and R&D spending.


Analysis · COCH · Industrial Applications And Services

Envoy Medical's Q2 2026 filing confirms the company remains a going concern with only $19.7 million in cash — enough to fund operations through the first quarter of 2027. The company burned $11.5 million in operating cash in the first half of the year, and its accumulated deficit has grown to $326 million. Material weaknesses in internal controls remain unremediated, adding governance risk. On the clinical front, all 56 patients in the pivotal Acclaim cochlear implant trial have passed the three-month milestone, and the first module of the PMA application has been submitted — but FDA approval is not expected until late 2027 at the earliest. The company's survival hinges on raising additional capital or exercising outstanding warrants, neither of which is assured.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 50% of the 206 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.71%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COCH was trading at $0.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $0.36 to $1.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COCH - Latest Insights

COCH
Aug 31, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $7.28 info
Change: Reverse Stock Split info
Market Cap: $56.343M info
COCH
Aug 19, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.740
Real-time Price: $7.28 info
Change: Reverse Stock Split info
Market Cap: $56.343M info
COCH
Aug 10, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.705
Real-time Price: $7.28 info
Change: Reverse Stock Split info
Market Cap: $56.343M info
COCH
Jul 21, 2026, 9:17 AM EDT
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $0.706
Real-time Price: $7.28 info
Change: Reverse Stock Split info
Market Cap: $56.343M info
COCH
Jul 14, 2026, 9:17 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.737
Real-time Price: $7.28 info
Change: Reverse Stock Split info
Market Cap: $56.343M info